Alpelisib

阿吡利塞

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAlpelisib
Drug Alias Name阿培利司alpelisibumAlpericivePiqrayVijoice +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsUveal melanomaPancreatic neuroendocrine tumors (pNET)Metastatic breast cancer +[31] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/05/24
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[51] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgColumbia UniversityNational Cancer Institute +[7] 
Inactive CompaniesThe University Of ArizonaH Lee Moffitt Cancer Center & Research InstituteYonsei University +[5] 
Active IndicationsMetastatic breast cancerPIK3CA-Related Overgrowth SpectrumDyslipidemias +[13] 
Inactive IndicationsUveal melanomaPancreatic neuroendocrine tumors (pNET)Solid tumours +[18] 

Other Information

ATC CodeL01EM03
Related LinksWikipediaDrugBankKEGG